LON:MXCT

MaxCyte Share Forecast, Price & News

GBX 387.50

+7.50 (+1.97%)

(As of 07/1/2022 05:06 PM ET)

Add

Compare

Today's Range: 370
▼
390
50-Day Range: 292
▼
450
52-Week Range: 280
▼
1,235

Volume: 11,462 shs
Average Volume: 70,884 shs
Market Capitalization: £393.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock Forecast (MarketRank)

Overall MarketRank^™

0.91 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for MaxCyte.

4.5 Community Rank

Outperform Votes
MaxCyte has received 152 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MaxCyte has received 69 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MaxCyte has received 68.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote “Outperform” if you believe MXCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MaxCyte does not currently pay a dividend.
Dividend Growth
MaxCyte does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MaxCyte insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of MaxCyte is -28.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MaxCyte is -28.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MaxCyte has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MaxCyte (LON:MXCT)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

May 13, 2022 | finance.yahoo.com

MaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 years

May 9, 2022 | seekingalpha.com

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | finanznachrichten.de

MaxCyte, Inc.: MaxCyte Reports First Quarter Financial Results

May 9, 2022 | finance.yahoo.com

MaxCyte Reports First Quarter Financial Results

April 20, 2022 | finance.yahoo.com

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

April 13, 2022 | marketwatch.com

MaxCyte CFO Resigns, Ron Holtz Appointed in Interim; Sees 1Q Revenue Up

April 13, 2022 | proactiveinvestors.com

MaxCyte sales surge, CFO stands down

April 12, 2022 | seekingalpha.com

MaxCyte reports CFO resignation and Q1 revenue estimate

March 23, 2022 | benzinga.com

MaxCyte's Return On Capital Employed Insights

March 22, 2022 | finance.yahoo.com

MaxCyte Reports Fourth Quarter and Full Year Financial Results

March 15, 2022 | finance.yahoo.com

Is MaxCyte, Inc. (LON:MXCT) Popular Amongst Institutions?

March 9, 2022 | finance.yahoo.com

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

February 24, 2022 | finance.yahoo.com

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:MXCT
CUSIP: N/A
CIK: N/A
Web: www.maxcyte.com
Phone: +1-301-9441700
Fax: N/A
Employees: 84
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 5.05
Current Ratio: 17.10
Quick Ratio: 16.53

Sales & Book Value

Annual Sales: £38.99 million
Price / Sales: 10.09
Cash Flow: GBX 240.95 per share
Price / Cash Flow: 1.61
Book Value: GBX 258.30 per share
Price / Book: 1.50

Miscellaneous

Outstanding Shares: 101,540,000
Free Float: N/A
Market Cap: £393.47 million
Optionable: Not Optionable
Beta: N/A

MaxCyte Frequently Asked Questions

How has MaxCyte's stock performed in 2022?: MaxCyte's stock was trading at GBX 755 at the start of the year. Since then, MXCT shares have decreased by 48.7% and is now trading at GBX 387.50.
View the best growth stocks for 2022 here.
Who are MaxCyte's key executives?: MaxCyte's management team includes the following people:
Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 66, Pay $1.39M)
Mr. Ronald Evan Holtz CPA, Ph.D., Chief Financial Officer (Age 64, Pay $649.38k)
Dr. J. Stark Thompson Ph.D., Consultant (Age 80, Pay $84.71k)
Dr. Cenk Sumen, Chief Scientific Officer (Age 49)
Mr. Sean Menarguez, Director of Investor Relations
Mr. Maher Masoud, Exec. VP, Gen. Counsel & Sec. (Age 47)
Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 61)
Mr. Kevin Gutshall, VP of Strategy & Corp. Devel.
Dr. James Brady Ph.D., Sr. VP of Technical Applications & Customer Support
Dr. Sarah Haecker Meeks Ph.D., Sr. VP of Bus. Devel.
Who are some of MaxCyte's key competitors?: Some companies that are related to MaxCyte include Sernova (SVA), Profound Medical (PRN), Profound Medical (PRN), Renalytix (RENX), Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), GENinCode (GENI) and genedrive (GDR).
View all of MXCT's competitors.
What other stocks do shareholders of MaxCyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?: MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."
How do I buy shares of MaxCyte?: Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is MaxCyte's stock price today?: One share of MXCT stock can currently be purchased for approximately GBX 387.50.
How much money does MaxCyte make?: MaxCyte (LON:MXCT) has a market capitalization of £393.47 million and generates £38.99 million in revenue each year.
How many employees does MaxCyte have?: MaxCyte employs 84 workers across the globe.
How can I contact MaxCyte?: MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The official website for MaxCyte is www.maxcyte.com. The company can be reached via phone at +1-301-9441700.

This page (LON:MXCT) was last updated on 7/1/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources